Complement Activation
Complement C3
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
Complement System Proteins
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Complement C4
Complement C5
C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX.
Receptors, Complement
Complement C3b
The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g.
Complement C1q
A subcomponent of complement C1, composed of six copies of three polypeptide chains (A, B, and C), each encoded by a separate gene (C1QA; C1QB; C1QC). This complex is arranged in nine subunits (six disulfide-linked dimers of A and B, and three disulfide-linked homodimers of C). C1q has binding sites for antibodies (the heavy chain of IMMUNOGLOBULIN G or IMMUNOGLOBULIN M). The interaction of C1q and immunoglobulin activates the two proenzymes COMPLEMENT C1R and COMPLEMENT C1S, thus initiating the cascade of COMPLEMENT ACTIVATION via the CLASSICAL COMPLEMENT PATHWAY.
Complement Pathway, Alternative
Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
Complement C9
A 63-kDa serum glycoprotein encoded by gene C9. Monomeric C9 (mC9) binds the C5b-8 complex to form C5b-9 which catalyzes the polymerization of C9 forming C5b-p9 (MEMBRANE ATTACK COMPLEX) and transmembrane channels leading to lysis of the target cell. Patients with C9 deficiency suffer from recurrent bacterial infections.
Complement Pathway, Classical
Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
Complement Membrane Attack Complex
A product of COMPLEMENT ACTIVATION cascade, regardless of the pathways, that forms transmembrane channels causing disruption of the target CELL MEMBRANE and cell lysis. It is formed by the sequential assembly of terminal complement components (COMPLEMENT C5B; COMPLEMENT C6; COMPLEMENT C7; COMPLEMENT C8; and COMPLEMENT C9) into the target membrane. The resultant C5b-8-poly-C9 is the "membrane attack complex" or MAC.
Complement Inactivator Proteins
Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.
Complement C2
A component of the CLASSICAL COMPLEMENT PATHWAY. C2 is cleaved by activated COMPLEMENT C1S into COMPLEMENT C2B and COMPLEMENT C2A. C2a, the COOH-terminal fragment containing a SERINE PROTEASE, combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
Complement Factor B
Complement Factor H
An important soluble regulator of the alternative pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It is a 139-kDa glycoprotein expressed by the liver and secreted into the blood. It binds to COMPLEMENT C3B and makes iC3b (inactivated complement 3b) susceptible to cleavage by COMPLEMENT FACTOR I. Complement factor H also inhibits the association of C3b with COMPLEMENT FACTOR B to form the C3bB proenzyme, and promotes the dissociation of Bb from the C3bBb complex (COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY).
Complement Inactivating Agents
Complement C3a
The smaller fragment generated from the cleavage of complement C3 by C3 CONVERTASE. C3a, a 77-amino acid peptide, is a mediator of local inflammatory process. It induces smooth MUSCLE CONTRACTION, and HISTAMINE RELEASE from MAST CELLS and LEUKOCYTES. C3a is considered an anaphylatoxin along with COMPLEMENT C4A; COMPLEMENT C5A; and COMPLEMENT C5A, DES-ARGININE.
Complement C5a
The minor fragment formed when C5 convertase cleaves C5 into C5a and COMPLEMENT C5B. C5a is a 74-amino-acid glycopeptide with a carboxy-terminal ARGININE that is crucial for its spasmogenic activity. Of all the complement-derived anaphylatoxins, C5a is the most potent in mediating immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE), smooth MUSCLE CONTRACTION; HISTAMINE RELEASE; and migration of LEUKOCYTES to site of INFLAMMATION.
Complement C6
A 105-kDa serum glycoprotein with significant homology to the other late complement components, C7-C9. It is a polypeptide chain cross-linked by 32 disulfide bonds. C6 is the next complement component to bind to the membrane-bound COMPLEMENT C5B in the assembly of MEMBRANE ATTACK COMPLEX. It is encoded by gene C6.
Receptors, Complement 3b
Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
Complement C1
The first complement component to act in the activation of CLASSICAL COMPLEMENT PATHWAY. It is a calcium-dependent trimolecular complex made up of three subcomponents: COMPLEMENT C1Q; COMPLEMENT C1R; and COMPLEMENT C1S at 1:2:2 ratios. When the intact C1 binds to at least two antibodies (involving C1q), C1r and C1s are sequentially activated, leading to subsequent steps in the cascade of COMPLEMENT ACTIVATION.
Complement C4b
Complement Activating Enzymes
Complement C3d
A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001).
Complement C3-C5 Convertases
Serine proteases that cleave COMPLEMENT C3 into COMPLEMENT C3A and COMPLEMENT C3B, or cleave COMPLEMENT C5 into COMPLEMENT C5A and COMPLEMENT C5B. These include the different forms of C3/C5 convertases in the classical and the alternative pathways of COMPLEMENT ACTIVATION. Both cleavages take place at the C-terminal of an ARGININE residue.
Complement Fixation Tests
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
Complement C7
A 93-kDa serum glycoprotein encoded by C7 gene. It is a polypeptide chain with 28 disulfide bridges. In the formation of MEMBRANE ATTACK COMPLEX; C7 is the next component to bind the C5b-6 complex forming a trimolecular complex C5b-7 which is lipophilic, resembles an integral membrane protein, and serves as an anchor for the late complement components, C8 and C9.
Complement C8
A 150-kDa serum glycoprotein composed of three subunits with each encoded by a different gene (C8A; C8B; and C8G). This heterotrimer contains a disulfide-linked C8alpha-C8gamma heterodimer and a noncovalently associated C8beta chain. C8 is the next component to bind the C5-7 complex forming C5b-8 that binds COMPLEMENT C9 and acts as a catalyst in the polymerization of C9.
Complement C3c
Receptors, Complement 3d
Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognize and combine with COMPLEMENT C3D. Human complement receptor 2 (CR2) serves as a receptor for both C3dg and the gp350/220 glycoprotein of HERPESVIRUS 4, HUMAN, and binds the monoclonal antibody OKB7, which blocks binding of both ligands to the receptor.
Complement Hemolytic Activity Assay
A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
Complement C3b Inactivator Proteins
Endogenous proteins that inhibit or inactivate COMPLEMENT C3B. They include COMPLEMENT FACTOR H and COMPLEMENT FACTOR I (C3b/C4b inactivator). They cleave or promote the cleavage of C3b into inactive fragments, and thus are important in the down-regulation of COMPLEMENT ACTIVATION and its cytolytic sequence.
Complement C4a
Complement Factor D
Complement Factor I
A plasma serine proteinase that cleaves the alpha-chains of C3b and C4b in the presence of the cofactors COMPLEMENT FACTOR H and C4-binding protein, respectively. It is a 66-kDa glycoprotein that converts C3b to inactivated C3b (iC3b) followed by the release of two fragments, C3c (150-kDa) and C3dg (41-kDa). It was formerly called KAF, C3bINF, or enzyme 3b inactivator.
Complement C4b-Binding Protein
Complement C1s
A 77-kDa subcomponent of complement C1, encoded by gene C1S, is a SERINE PROTEASE existing as a proenzyme (homodimer) in the intact complement C1 complex. Upon the binding of COMPLEMENT C1Q to antibodies, the activated COMPLEMENT C1R cleaves C1s into two chains, A (heavy) and B (light, the serine protease), linked by disulfide bonds yielding the active C1s. The activated C1s, in turn, cleaves COMPLEMENT C2 and COMPLEMENT C4 to form C4b2a (CLASSICAL C3 CONVERTASE).
Complement C1r
A 80-kDa subcomponent of complement C1, existing as a SERINE PROTEASE proenzyme in the intact complement C1 complex. When COMPLEMENT C1Q is bound to antibodies, the changed tertiary structure causes autolytic activation of complement C1r which is cleaved into two chains, A (heavy) and B (light, the serine protease), connected by disulfide bonds. The activated C1r serine protease, in turn, activates COMPLEMENT C1S proenzyme by cleaving the Arg426-Ile427 bond. No fragment is released when either C1r or C1s is cleaved.
Antigens, CD55
Antigens, CD59
Complement C1 Inactivator Proteins
Complement C5b
The larger fragment generated from the cleavage of C5 by C5 CONVERTASE that yields COMPLEMENT C5A and C5b (beta chain + alpha' chain, the residual alpha chain, bound by disulfide bond). C5b remains bound to the membrane and initiates the spontaneous assembly of the late complement components to form C5b-8-poly-C9, the MEMBRANE ATTACK COMPLEX.
Complement Pathway, Mannose-Binding Lectin
Complement activation triggered by the interaction of microbial POLYSACCHARIDES with serum MANNOSE-BINDING LECTIN resulting in the activation of MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. As in the classical pathway, MASPs cleave COMPLEMENT C4 and COMPLEMENT C2 to form C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
Properdin
A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections.
Cobra Venoms
Hemolysis
Complement C1 Inhibitor Protein
An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.
Anaphylatoxins
Serum peptides derived from certain cleaved COMPLEMENT PROTEINS during COMPLEMENT ACTIVATION. They induce smooth MUSCLE CONTRACTION; mast cell HISTAMINE RELEASE; PLATELET AGGREGATION; and act as mediators of the local inflammatory process. The order of anaphylatoxin activity from the strongest to the weakest is C5a, C3a, C4a, and C5a des-arginine.
Complement C3 Convertase, Alternative Pathway
Antigens, CD46
Receptor, Anaphylatoxin C5a
Genetic Complementation Test
Antigen-Antibody Complex
Opsonin Proteins
Immunoglobulin G
Molecular Sequence Data
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Phagocytosis
Blood Bactericidal Activity
The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST.
Mannose-Binding Lectin
Amino Acid Sequence
Macrophage-1 Antigen
Erythrocytes
Mannose-Binding Protein-Associated Serine Proteases
Serum serine proteases which participate in COMPLEMENT ACTIVATION. They are activated when complexed with the MANNOSE-BINDING LECTIN, therefore also known as Mannose-binding protein-Associated Serine Proteases (MASPs). They cleave COMPLEMENT C4 and COMPLEMENT C2 to form C4b2a, the CLASSICAL PATHWAY C3 CONVERTASE.
Immunoglobulin M
Complement C5a, des-Arginine
Neutrophils
Protein Binding
Base Sequence
Mutation
Antibodies
Rabbits
Collectins
A class of C-type lectins that target the carbohydrate structures found on invading pathogens. Binding of collectins to microorganisms results in their agglutination and enhanced clearance. Collectins form trimers that may assemble into larger oligomers. Each collectin polypeptide chain consists of four regions: a relatively short N-terminal region, a collagen-like region, an alpha-helical coiled-coil region, and carbohydrate-binding region.
Macular Degeneration
Cloning, Molecular
Blood Proteins
Guinea Pigs
Immune Adherence Reaction
A method for the detection of very small quantities of antibody in which the antigen-antibody-complement complex adheres to indicator cells, usually primate erythrocytes or nonprimate blood platelets. The reaction is dependent on the number of bound C3 molecules on the C3b receptor sites of the indicator cell.
Enzyme-Linked Immunosorbent Assay
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Escherichia coli
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
Immunoelectrophoresis
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Fluorescent Antibody Technique
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Glomerulonephritis
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
Hemoglobinuria, Paroxysmal
A condition characterized by the recurrence of HEMOGLOBINURIA caused by intravascular HEMOLYSIS. In cases occurring upon cold exposure (paroxysmal cold hemoglobinuria), usually after infections, there is a circulating antibody which is also a cold hemolysin. In cases occurring during or after sleep (paroxysmal nocturnal hemoglobinuria), the clonal hematopoietic stem cells exhibit a global deficiency of cell membrane proteins.
Immune Complex Diseases
Group of diseases mediated by the deposition of large soluble complexes of antigen and antibody with resultant damage to tissue. Besides SERUM SICKNESS and the ARTHUS REACTION, evidence supports a pathogenic role for immune complexes in many other IMMUNE SYSTEM DISEASES including GLOMERULONEPHRITIS, systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC) and POLYARTERITIS NODOSA.
Immunoglobulins
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
Cells, Cultured
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Immunodiffusion
Binding Sites
Complement C2b
Cryoglobulins
Lectins
Proteins that share the common characteristic of binding to carbohydrates. Some ANTIBODIES and carbohydrate-metabolizing proteins (ENZYMES) also bind to carbohydrates, however they are not considered lectins. PLANT LECTINS are carbohydrate-binding proteins that have been primarily identified by their hemagglutinating activity (HEMAGGLUTININS). However, a variety of lectins occur in animal species where they serve diverse array of functions through specific carbohydrate recognition.
Mice, Knockout
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Sequence Homology, Amino Acid
Immunity, Innate
Sheep
Cytotoxicity, Immunologic
Macrophages
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
Antigen-Antibody Reactions
Dose-Response Relationship, Immunologic
Species Specificity
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
Electrophoresis, Polyacrylamide Gel
Autoantibodies
Binding Sites, Antibody
Disease Models, Animal
Glycoproteins
Kidney Glomerulus
Serum
Rosette Formation
The in vitro formation of clusters consisting of a cell (usually a lymphocyte) surrounded by antigenic cells or antigen-bearing particles (usually erythrocytes, which may or may not be coated with antibody or antibody and complement). The rosette-forming cell may be an antibody-forming cell, a memory cell, a T-cell, a cell bearing surface cytophilic antibodies, or a monocyte possessing Fc receptors. Rosette formation can be used to identify specific populations of these cells.
Phenotype
Peptide Fragments
RNA, Messenger
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Protein Structure, Tertiary
The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.
Glomerulonephritis, Membranoproliferative
Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
Antigens, CD
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Antibody-Dependent Cell Cytotoxicity
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
gamma-Globulins
Serum globulins that migrate to the gamma region (most positively charged) upon ELECTROPHORESIS. At one time, gamma-globulins came to be used as a synonym for immunoglobulins since most immunoglobulins are gamma globulins and conversely most gamma globulins are immunoglobulins. But since some immunoglobulins exhibit an alpha or beta electrophoretic mobility, that usage is in decline.
Complement C3 Convertase, Classical Pathway
Antigens, Surface
Cricetinae
Surface Plasmon Resonance
A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.
Flow Cytometry
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Immunoglobulin Fc Fragments
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Membrane Proteins
Carrier Proteins
Arthus Reaction
Sequence Alignment
The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.
Antibody Specificity
Plasmids
B-Lymphocytes
Monocytes
Saccharomyces cerevisiae
Edetic Acid
Receptors, IgG
Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).
Inflammation
Angioedema
Bacterial Outer Membrane Proteins
Lipopolysaccharides
Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed)
DNA
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Receptors, Fc
Cell Membrane
Antibody Formation
Models, Molecular
Leukocytes
Neutralization Tests
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Blotting, Western
T-Lymphocytes
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Microscopy, Electron
Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.
CHO Cells
Integrin alphaXbeta2
Clusterin
Serum Globulins
Streptococcus pneumoniae
Erythrocyte Membrane
Gene Expression Regulation
Gene Deletion
Sequence Analysis, DNA
Histocompatibility Antigens
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Immunoglobulin A
Mice, Inbred Strains
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Recombinant Fusion Proteins
Neisseria meningitidis
A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype.
Immunization, Passive
Reperfusion Injury
Hemagglutination Tests
Chromium Isotopes
Immunohistochemistry
Kidney
Protein Conformation
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
Serine Endopeptidases
Chemotaxis, Leukocyte
Temperature
Snake Venoms
Rheumatoid Factor
Isoantibodies
Complement activity and pharmacological inhibition in cardiovascular disease. (1/54)
While complement is the most important component of humoral autoimmunity, and inflammation plays a key role in atherosclerosis, relatively few studies have looked at complement implications in atherosclerosis and its complications. C-reactive protein is a marker of inflammation and is also involved in atherosclerosis; it activates complement and colocalizes with activated complement proteins within the infarcting myocardium and the active atherosclerotic plaques. As new agents capable of modulating complement activity are being developed, new targets for the management of atherosclerosis are emerging that are related to autoimmunity and inflammation. The present paper reviews the putative roles of the various complement activation pathways in the development of atherosclerosis, in ST segment elevation and non-ST segment elevation acute coronary syndromes, and in coronary artery bypass graft surgery. It also provides a perspective on new therapeutic interventions being developed to modulate complement activity. These interventions include the C1 esterase inhibitor, which may be consumed in some inflammatory states resulting in the loss of one of the mechanisms inhibiting activation of the classical and lectin pathways; TP10, a recombinant protein of the soluble complement receptor type 1 (sCR1) which inhibits the C3 and C5 convertases of the common pathway by binding C3b and C4b; a truncated version of the soluble complement receptor type 1 CRI lacking the C4b binding site which selectively inhibits the alternative pathway; and pexelizumab, a monoclonal antibody selectively blocking C5 to prevent the activation of the terminal pathway that is involved in excessive inflammation and autoimmune responses. (+info)Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. (2/54)
A shortage of donor organs and increasing dependence on marginal grafts with prolonged ischemic times have meant that new methods are needed to prevent postischemic damage. Herein is reported a new strategy aimed to protect donor kidney from complement-mediated postischemic damage and therefore increase the number of successful transplants. Rat donor kidneys were perfused with a membrane-localizing complement regulator derived from human complement receptor type 1 (APT070) and then subjected to prolonged periods of cold storage (at 4 degrees C). A relationship was found between the duration of cold ischemia and the extent of complement-mediated tubule damage and loss of graft function. After 16 h of cold storage, APT070-treated kidneys that were transplanted into syngeneic recipients showed a significant increase in the number of surviving grafts, compared with control-treated grafts (63.6 versus 26.3%). Surviving grafts also displayed less acute tubular injury and better preservation of renal function. These results not only enhance the understanding of the mechanism by which prolonged cold ischemia reduces immediate graft survival but also provide essential information about the effectiveness of membrane-localizing complement regulator with prolonged cold storage. This could lead to more effective strategies for improving the use of severely ischemic donor organs. (+info)Relapsing fever spirochetes Borrelia recurrentis and B. duttonii acquire complement regulators C4b-binding protein and factor H. (3/54)
Relapsing fever is a rapidly progressive and severe septic disease caused by certain Borrelia spirochetes. The disease is divided into two forms, i.e., epidemic relapsing fever, caused by Borrelia recurrentis and transmitted by lice, and the endemic form, caused by several Borrelia species, such as B. duttonii, and transmitted by soft-bodied ticks. The spirochetes enter the bloodstream by the vector bite and live persistently in plasma even after the development of specific antibodies. This leads to fever relapses and high mortality and clearly indicates that the Borrelia organisms utilize effective immune evasion strategies. In this study, we show that the epidemic relapsing fever pathogen B. recurrentis and an endemic relapsing fever pathogen, B. duttonii, are serum resistant, i.e., resistant to complement in vitro. They acquire the host alternative complement pathway regulator factor H on their surfaces in a similar way to that of the less serum-resistant Lyme disease pathogen, B. burgdorferi sensu stricto. More importantly, the relapsing fever spirochetes specifically bind host C4b-binding protein, a major regulator of the antibody-mediated classical complement pathway. Both complement regulators retained their functional activities when bound to the surfaces of the spirochetes. In conclusion, this is the first report of complement evasion by Borrelia recurrentis and B. duttonii and the first report showing capture of C4b-binding protein by spirochetes. (+info)A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. (4/54)
Complement is an important component of the innate and adaptive immune response, yet complement split products generated through activation of each of the three complement pathways (classical, alternative, and lectin) can cause inflammation and tissue destruction. Previous studies have shown that complement activation through the alternative, but not classical, pathway is required to initiate antibody-induced arthritis in mice, but it is unclear if the alternative pathway (AP) plays a role in established disease. Previously, we have shown that human complement receptor of the immunoglobulin superfamily (CRIg) is a selective inhibitor of the AP of complement. Here, we present the crystal structure of murine CRIg and, using mutants, provide evidence that the structural requirements for inhibition of the AP are conserved in human and mouse. A soluble form of CRIg reversed inflammation and bone loss in two experimental models of arthritis by inhibiting the AP of complement in the joint. Our data indicate that the AP of complement is not only required for disease induction, but also disease progression. The extracellular domain of CRIg thus provides a novel tool to study the effects of inhibiting the AP of complement in established disease and constitutes a promising therapeutic with selectivity for a single complement pathway. (+info)Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. (5/54)
We report here the discovery and characterization of Ehp, a new secreted Staphylococcus aureus protein that potently inhibits the alternative complement activation pathway. Ehp was identified through a genomic scan as an uncharacterized secreted protein from S. aureus, and immunoblotting of conditioned S. aureus culture medium revealed that the Ehp protein was secreted at the highest levels during log-phase bacterial growth. The mature Ehp polypeptide is composed of 80 residues and is 44% identical to the complement inhibitory domain of S. aureus Efb (extracellular fibrinogen-binding protein). We observed preferential binding by Ehp to native and hydrolyzed C3 relative to fully active C3b and found that Ehp formed a subnanomolar affinity complex with these various forms of C3 by binding to its thioester-containing C3d domain. Site-directed mutagenesis demonstrated that Arg(75) and Asn(82) are important in forming the Ehp.C3d complex, but loss of these side chains did not completely disrupt Ehp/C3d binding. This suggested the presence of a second C3d-binding site in Ehp, which was mapped to the proximity of Ehp Asn(63). Further molecular level details of the Ehp/C3d interaction were revealed by solving the 2.7-A crystal structure of an Ehp.C3d complex in which the low affinity site had been mutationally inactivated. Ehp potently inhibited C3b deposition onto sensitized surfaces by the alternative complement activation pathway. This inhibition was directly related to Ehp/C3d binding and was more potent than that seen for Efb-C. An altered conformation in Ehp-bound C3 was detected by monoclonal antibody C3-9, which is specific for a neoantigen exposed in activated forms of C3. Our results suggest that increased inhibitory potency of Ehp relative to Efb-C is derived from the second C3-binding site in this new protein. (+info)Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. (6/54)
Hemolysis and hemoglobinemia contribute to serious clinical sequelae in hemolytic disorders. In paroxysmal nocturnal hemoglobinuria (PNH) patients, hemolysis can contribute to thromboembolism (TE), the most feared complication in PNH, and the leading cause of disease-related deaths. We evaluated whether long-term treatment with the complement inhibitor eculizumab reduces the rate of TE in patients with PNH. Clinical trial participants included all patients in the 3 eculizumab PNH clinical studies, which recruited patients between 2002 and 2005 (n = 195); patients from these studies continued treatment in the current multinational open-label extension study. Thromboembolism rate with eculizumab treatment was compared with the pretreatment rate in the same patients. The TE event rate with eculizumab treatment was 1.07 events/100 patient-years compared with 7.37 events/100 patient-years (P < .001) prior to eculizumab treatment (relative reduction, 85%; absolute reduction, 6.3 TE events/100 patient-years). With equalization of the duration of exposure before and during treatment for each patient, TE events were reduced from 39 events before eculizumab to 3 events during eculizumab (P < .001). The TE event rate in antithrombotic-treated patients (n = 103) was reduced from 10.61 to 0.62 events/100 patient-years with eculizumab treatment (P < .001). These results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH. This study is registered at http://clinicaltrials.gov (study ID no. NCT00122317). (+info)Management of hereditary angioedema in pediatric patients. (7/54)
Hereditary angioneurotic edema is a rare disorder caused by the congenital deficiency of C1 inhibitor. Recurring angioedematous paroxysms that most commonly involve the subcutis (eg, extremities, face, trunk, and genitals) or the submucosa (eg, intestines and larynx) are the hallmarks of hereditary angioneurotic edema. Edema formation is related to reduction or dysfunction of C1 inhibitor, and conventional therapy with antihistamines and corticosteroids is ineffective. Manifestations occur during the initial 2 decades of life, but even today there is a long delay between the onset of initial symptoms and the diagnosis of hereditary angioneurotic edema. Although a variety of reviews have been published during the last 3 decades on the general management of hereditary angioneurotic edema, little has been published regarding management of pediatric hereditary angioneurotic edema. Thus, we review our experience and published data to provide an approach to hereditary angioneurotic edema in childhood. (+info)Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. (8/54)
OBJECTIVE: Both increased production of reactive oxygen and nitrogen intermediates (RONI) and reduced levels of complement may play a role in the increased apoptosis and reduced clearance of apoptotic cells in systemic lupus erythematosus (SLE). The objective of this study was to evaluate both processes in a parallel, prospective, longitudinal manner. METHODS: Sixty-seven SLE patients were evaluated during multiple visits, and 31 healthy control subjects were evaluated once or twice. Clinical and laboratory features of SLE disease activity were determined, and blood was collected for measurement of serum nitrate plus nitrite (NOx) levels and for isolation of peripheral blood mononuclear cells (PBMCs). PBMCs were cultured with a nitric oxide (NO) donor and SLE or control plasma, with or without heat inactivation, cobra venom factor (CVF), or lipopolysaccharide plus interferon-gamma treatment. Cells were analyzed for apoptotic index (AI), cellular subsets, and RONI production. RESULTS: The PBMC AI was associated with SLE and was inversely associated with complement levels over time. Changes in the AI with addition of a NO donor was longitudinally associated with serum NOx levels, and stimulation of SLE PBMCs led to parallel increases in RONI production and apoptosis. Addition of SLE plasma resulted in a greater PBMC AI, an effect that was increased with heat inactivation and was corrected with CVF treatment. CONCLUSION: These data suggest that the greater AI observed in SLE PBMCs relates to increased PBMC RONI production and reduced complement levels. The longitudinal nature of these parallel associations within individuals suggests that these processes are dynamic and additive. (+info)
Complement evasion strategies of microorganisms
Quick Fix For Hair Fall
Oral Delivery of Protein Complement Inhibitor | Society for Mucosal Immunology
Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice<...
Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-binding protein.
Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor...
Ultrasonic Solution Long Term Rust Inhibitor Chem-Crest 77-C
EHP Labs RP Max Review: Effective, But Theres a Catch..
A Structural Basis for Complement Inhibition by Staphylococcus Aureus
EHP Labs Beyond BCAA Review - Sportys Health
ERPtek SAP HR/HCM with ERP 6.0 EHP7 Certification Course Details.
Wolves-San Antonio preview - StarTribune.com
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers - Full Text View -...
Impact of donor and recipient smoke exposure on lung post-transplant outcomes : implications for complement inhibition ::...
Epigenetic stabilization of DC and DC precursor classical activation by TNFα contributes to protective T cell polarization |...
Steve Tomlinson Faculty Page
SBI PO Exam Pattern |SBI PO Recruitment | SBI PO Eligibility
Safety of C1-Esterase Inhibitor in Acute and Prophylactic Therapy of Hereditary Angioedema - Danish National Research Database...
Bowman-Birk Inhibitor Concentrate - AdisInsight
Frontiers | Complement Evasion Strategies of Viruses: An Overview | Microbiology
The expression of C1 inhibitor (C1INH) in macrophages is upregulated by retinal pigment epithelial cells - implication in...
Microbial complement inhibitors as vaccines. - NextBio article
Eculizumab in Dialysis - Renal Pharmacists Network
Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor<...
Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor
Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. | OnMedica
C4BP runs damage control | JEM
Feasibility of home infusion and self-administration of nanofi...
Compstatin Cp40 (AMY-101): a C3-targeted complement inhibitor reaching its prime for bedside intervention | Boulder Peptide...
Dopamine D2 Receptors
Anti-IL-6R mABs for Rheumatoid Arthritis - Evidentic
Buy OxyShred | Non-Stim by EHP Labs online - EHPlabs
Hereditary Angioedema - Andy Long Bass Player
Hereditary Angioedema
Hereditary Angioedema Risk Factors, Symptoms and Ways to Live Better - Sharecare
What is Hereditary Angioedema? - Hereditary Angioedema Definition - GoodRx
Hereditary Angioedema
Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis
Shires Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase...
Monitoring Your Hereditary Angioedema Triggers
Clinical review of hereditary angioedema: diagnosis and management.
Hereditary angioedema with normal C1 inhibitor
Henrik Balle Boysen, Author at HAE International (HAEi)
US Hereditary Angioedema Association - HAEA
Hereditary Angioedema Market to be Worth US$3.81 Billion by 2025: Initiatives to Generate Awareness
Hereditary Angioedema Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012...
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N - Full Text View - ClinicalTrials.gov
Heavy metal-induced activation of the murine immune system and autoimmunity : a comparative study of mercury and silver
A Patients Journey to a Hereditary Angioedema (HAE) Diagnosis
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema...
ViroPharma Launches Ryze Above(TM), A Personalized Patient Resources Program For Patients With Hereditary Angioedema (HAE)
Complement pathway may be involved in ARMD.
Pharma: Clinic Roundup
Blog Archives - EHP ECUMENICAL HUNGER PROGRAM
Therapeutic focus - Pharvaris
Wall Streets Augury: BioCryst Pharmaceuticals (Nasdaq:BCR
Cinryze Dosage
Meet Stacey, a Shire Caregiver Ambassador
BacMam
Furthermore, BacMam viruses are inactivated by human complement, which reduces risk to researchers. Lastly, viruses used in the ... Baculoviruses are Risk Group 1 agents that have been widely used for over 25 years for insect cell protein production ... "Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system ...
List of MeSH codes (D27)
... immunosuppressive agents MeSH D27.505.696.477.656.500 - complement inactivating agents MeSH D27.505.696.477.656.750 - ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ... tranquilizing agents MeSH D27.505.696.277.950.015 - anti-anxiety agents MeSH D27.505.696.277.950.025 - antimanic agents MeSH ...
Complementary DNA
Importantly, RNA integrity is maintained by inactivating RNases with chaotropic agents such as guanidinium isothiocyanate, ... mRNA is selectively reverse transcribed using oligo-dT primers that are the reverse complement of the poly-adenylated tail on ...
Germinal center B-cell like diffuse large B-cell lymphoma
Combining ABT-737 with second agents that inactivate Mcl-1 may reduce this effect. ABT-737 has demonstrated single-agent ... and natural killer cells to destroy the targeted cells Complement-dependent cytotoxicity (CDC)-- Initiates the complement ... Cell death does not appear to be mediated by complement, but modest antibody-dependent cellular cytotoxicity and direct killing ... Reduced susceptibility to apoptosis increases the resistance of cancer cells to radiation and cytotoxic agents. B-cell lymphoma ...
Daratumumab
"Janssen's Single-Agent Darzalex (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)". ... Daratumumab binds to CD38, causing cells to apoptose via antibody-dependent cellular cytotoxicity, complement-dependent ... DTT also inactivates/destroys many antigens on the red blood cell surface by disrupting disulfide bonds. The only antigen ... Updated trial results presented in December 2012, indicate daratumumab is continuing to show promising single-agent anti- ...
Kyasanur Forest disease
Studies began to look for the possible species that acted as reservoirs for the virus and the agents responsible for ... The vaccine for KFDV consists of formalin-inactivated KFDV. The vaccine has a 62.4% effectiveness rate for individuals who ... Other methods of diagnosis included hemagglutination inhibition (HI), complement fixation, neutralization tests. However, new ...
Infection
First, the catalog of infectious agents has grown to the point that virtually all of the significant infectious agents of the ... This process requires immune mechanisms to kill or inactivate the inoculum of the pathogen. Specific acquired immunity against ... such as antibody-initiated complement-dependent bacteriolysis, opsonoization, phagocytosis and killing, as occurs for some ... Second, an infectious agent must grow within the human body to cause disease; essentially it must amplify its own nucleic acids ...
Adenylate cyclase toxin
Adenylate cyclese toxin binds to target cells by the complement receptor 3 (CD11b/CD18, or Mac-1). Target cell are therefore ... Together with the pertussis toxin it is the most important virulence factor of the causative agent of whooping cough, ... Besides attachment to bacterial proteins, aggregation also inactivates the toxin. This quick inactivation highlights the ...
Specialized pro-resolving mediators
Hence, the classic inflammatory response was viewed as fully regulated by the soluble signaling agents. That is, the agents ... complement components C5a and C3a which are chemotactic factors formed during the activation of the host's blood complement ... However, studies suggest that synthetic SPM that are resistant to being metabolically inactivated hold promise of being ... While initially found to have in vitro activity suggesting that they might act as pro-inflammatory agents, Serhan and ...
Hepatocyte
... s have the ability to metabolize, detoxify, and inactivate exogenous compounds such as drugs (see drug metabolism), ... in which calcium is removed to disrupt cell-cell tight junctions by the use of a calcium chelating agent. Next, a solution ... complement, and glycoproteins. Hepatocytes manufacture their own structural proteins and intracellular enzymes. Synthesis of ... "Wheat extracts as an efficient cryoprotective agent for primary cultures of rat hepatocytes". Biotechnology and Bioengineering ...
MTOR
Li W, Qin L, Feng R, Hu G, Sun H, He Y, Zhang R (July 2019). "Emerging senolytic agents derived from natural products". ... Additionally, several types of ubiquitination events parallel and complement the galectin-driven processes: Ubiquitination of ... of the autophagy systems listed above and further inactivates mTORC1, allows for strong autophagy induction and autophagic ... mTOR is inhibited when lysosomal membrane is damaged by various exogenous or endogenous agents, such as invading bacteria, ...
Fibrinolysis
Tissue plasminogen activator (t-PA) and urokinase are the agents that convert plasminogen to the active plasmin, thus allowing ... Plasmin, in addition to lysing fibrin clots, also cleaves the complement system component C3, and fibrin degradation products ... Alpha 2-antiplasmin and alpha 2-macroglobulin inactivate plasmin. Plasmin activity is also reduced by thrombin-activatable ... Thrombolysis refers to the dissolution of the thrombus due to various agents while fibrinolysis refers specifically to the ...
Oncolytic virus
becoming the first approved oncolytic agent in the western world. It is based on herpes simplex virus (HSV-1). It has also been ... Although it poses a hurdle by inactivating viruses, the patient's immune system can also act as an ally against tumors; ... Magge D, Guo ZS, O'Malley ME, Francis L, Ravindranathan R, Bartlett DL (June 2013). "Inhibitors of C5 complement enhance ... Directed evolution was applied on human adenovirus, one of many viruses that are being developed as oncolytic agents, to create ...
Lymphocytic choriomeningitis
Its causative agent is lymphocytic choriomeningitis mammarenavirus (LCMV), a member of the family Arenaviridae. The name was ... However, some authors note that such complement-fixation tests are insensitive and should not be used for diagnosis. Dr. Clare ... In addition, LCMV can also be inactivated by heat, ultraviolet light or gamma irradiation. Studies have indicated that human ... Such agents had been developed in the animal care facility, which periodically screened sentinel animals for extraneous ...
Streptococcus dysgalactiae
The M-protein aids in immune evasion by inhibiting phagocytosis and inactivating the complement system. Furthermore, ... Second-line agents include macrolides and clindamycin, although increasing resistance, due to both efflux and target ... Antimicrobial Agents and Chemotherapy. 19 (5): 716-725. doi:10.1128/aac.19.5.716. ISSN 0066-4804. PMC 181512 . PMID 7027921. ...
Restriction modification system
The human genome already contains remnants of retroviral genomes that have been inactivated and harnessed for self-gain. Indeed ... This prevents infection by effectively destroying the foreign DNA introduced by an infectious agent (such as a bacteriophage). ... and excision repair cross complementing 1(ERCC) appear to mimic the action of RM-systems in bacteria, and the non-homologous ... gene transfer agents or generalized transduction in order to move between genomes. Methylation Restriction enzyme Luria SE, ...
Vaccine
Inactivated. Main article: Inactivated vaccine. Some vaccines contain inactivated, but previously virulent, micro-organisms ... The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and ... Meri S, Jördens M, Jarva H (December 2008). "Microbial complement inhibitors as vaccines". Vaccine. 26 Suppl 8: I113-7. doi: ... Formaldehyde is used to inactivate bacterial products for toxoid vaccines. Formaldehyde is also used to inactivate unwanted ...
Antineoplastic resistance
... as the electrophilic properties of glutathione allow it to react with cytotoxic agents, inactivating them. In some cases, ... The cisplatin-resistant cells upregulate expression of the excision repair cross-complementing (ERCC1) gene and protein. Some ... In colorectal cancer cells, inhibition of NF-κB or MDR1 caused increased apoptosis in response to a chemotherapeutic agent. ... 2004-07-15). "Oncogenic H-Ras Up-Regulates Expression of ERCC1 to Protect Cells from Platinum-Based Anticancer Agents". Cancer ...
Influenza research
Agents Chemother. 50 (11): 3724-33. doi:10.1128/AAC.00644-06. PMC 1635187. PMID 16966399. Gabriel, G; Nordmann A; Stein DA; ... Lindequist U, Niedermeyer TH, Jülich WD (September 2005). "The pharmacological potential of mushrooms". Evid Based Complement ... "Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine". N Engl J Med. 354 (13): 1343-51. doi:10.1056 ... NIAID contracted with Chiron Corporation to produce investigational batches of an inactivated vaccine, which will be evaluated ...
Pneumonia
A causative agent may not be isolated in about half of cases despite careful testing. In an active population-based ... In the lower airways, reflexes of the glottis, actions of complement proteins and immunoglobulins are important for protection ... attempt to inactivate the bacteria. The neutrophils also release cytokines, causing a general activation of the immune system. ... The causative agent is determined in only 15% of cases with routine microbiological tests. Pneumonitis refers to lung ...
RAF Harrington
The squadrons flew agents and supplies into southern France with B-24 Liberators that had all armament removed except in the ... When assigned to Harrington, the 801st Bombardment Group (Provisional) was inactivated in a name-only manner. Headquarters and ... HHS 39th Service Group 18th Weather Squadron 35th Station Complement Squadron Regular Army Station Units included: Headquarters ... However, the Japanese surrender canceled those plans and the Group was inactivated in October. After the war, Harrington ...
Poly (ADP-ribose) polymerase
Note below that PARP is inactivated by caspase-3 cleavage during programmed cell death. PARP enzymes are essential in a number ... DNA damage theory of aging Maximum life span PARP1 PARP inhibitor class of anti-cancer agents Parthanatos Senescence Herceg Z, ... and scaffolding proteins such as X-ray cross-complementing gene 1 (XRCC1). After repairing, the PAR chains are degraded via ... Cleavage of PARP, by enzymes such as caspases or cathepsins, typically inactivates PARP. The size of the cleavage fragments can ...
Vaccine
Rather than introducing an inactivated or attenuated micro-organism to an immune system (which would constitute a "whole-agent ... Meri S, Jördens M, Jarva H (December 2008). "Microbial complement inhibitors as vaccines". Vaccine. 26 Suppl 8: I113-7. doi: ... The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and ... Formaldehyde is used to inactivate bacterial products for toxoid vaccines. Formaldehyde is also used to inactivate unwanted ...
Enterovirus
... A71 (EV-A71) is notable as one of the major causative agents for hand, foot and mouth disease (HFMD), and is ... There are two types of vaccines available to prevent polio: inactivated poliovirus vaccine given as an injection in the leg ( ... complement proteins, and proapoptotis proteins have been implicated. There are three serotypes of poliovirus, PV-1, PV-2, and ...
Angioedema
These agents increase the level of aminopeptidase P, an enzyme that inactivates kinins;[22] kinins (especially bradykinin) are ... All forms of HAE lead to abnormal activation of the complement system, and all forms can cause swelling elsewhere in the body, ... In this analysis, it is usually a reduced complement factor C4, rather than the C1-INH deficiency itself, that is detected. The ... In hereditary angioedema, bradykinin formation is caused by continuous activation of the complement system due to a deficiency ...
Protein kinase
... signals that inactivate the phosphatases that restrict a given MAP kinase. Such signals include oxidant stress. Tyrosine- ... "The protein kinase complement of the human genome". Science. 298 (5600): 1912-1934. doi:10.1126/science.1075762. PMID 12471243 ... either natural ligands or crosslinking agents) and proteins associated with them (mutations that simulate active state) b) ...
Angioedema
These agents increase the level of aminopeptidase P, an enzyme that inactivates kinins; kinins (especially bradykinin) are ... All forms of HAE lead to abnormal activation of the complement system, and all forms can cause swelling elsewhere in the body, ... In this analysis, it is usually a reduced complement factor C4, rather than the C1-INH deficiency itself, that is detected. The ... The version related to histamine is due to an allergic reaction to agents such as insect bites, foods, or medications. The ...
Xenotransplantation
The binding of XNAs initiate complement activation through the classical complement pathway. Complement activation causes a ... Baboons and pigs carry myriad transmittable agents that are harmless in their natural host, but extremely toxic and deadly in ... Pig cells have been engineered to inactivate all 62 PERVs in the genome using CRISPR Cas9 genome editing technology,[42] and ... Interruption of the complement cascade *The recipient's complement cascade can be inhibited through the use of cobra venom ...
Vaccine
Rather than introducing an inactivated or attenuated micro-organism to an immune system (which would constitute a "whole-agent ... Meri S, Jördens M, Jarva H (December 2008). "Microbial complement inhibitors as vaccines". Vaccine. 26 Suppl 8: I113-7. doi: ... Inactivated. Main article: Inactivated vaccine. Some vaccines contain inactivated, but previously virulent, micro-organisms ... The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and ...
Lyme disease
... inactivating key immune components such as complement, and hiding in the extracellular matrix, which may interfere with the ... After the identification of B. burgdorferi as the causative agent of Lyme disease, antibiotics were selected for testing, ... The resistance of a genospecies of Lyme disease spirochetes to the bacteriolytic activities of the alternative complement ... Former Ocean County Agricultural Agent and George C. Hamilton, PhD, Extension Specialist in Pest Management, March 2005. ...
Pasteur Institute
Alphonse Laveran got the 1907 Nobel Prize for his research on the role of protozoans as disease agents (notably, his discovery ... 112 They concluded that a series of three or four early injections of such heat-inactivated bacteria can effectively inoculate ... especially the implication of antibodies and the mechanisms of action of the complement; ... between Pasteur and Berthelot after the publication of Claude Bernard's posthumous essay regarding the nature of the agents ...
Factor X
... a is inactivated by protein Z-dependent protease inhibitor (ZPI), a serine protease inhibitor (serpin). The affinity of ... These agents known as vitamin K antagonists (VKA), inhibit the vitamin K-dependent carboxylation of Factors II (prothrombin), ... These agents have several theoretical advantages over current therapy. They may be given orally. They have rapid onset of ... LMWH shows increased inactivation of Factor Xa compared to unfractionated heparin, and fondaparinux, an agent based on the ...
Autoimmunity
Clonal Anergy theory, proposed by Nossal, in which self-reactive T- or B-cells become inactivated in the normal individual and ... Certain chemical agents and drugs can also be associated with the genesis of autoimmune conditions, or conditions that simulate ... These ligands include B cell receptor (for antigen), IgG Fc receptors, CD21, which binds complement C3d, Toll-like receptors 9 ... Specific immunomodulatory therapies, such as the TNFα antagonists (e.g. etanercept), the B cell depleting agent rituximab, the ...
Secondary hypertension
Medications commonly associated with rebound hypertension include centrally-acting antihypertensive agents, such as clonidine[ ... an enzyme that normally inactivates circulating cortisol to the less-active metabolite cortisone.[16] At high concentrations ... "Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis". Thrombosis and Haemostasis. 101 ...
Adalimumab
... is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor- ... Similar agents[edit]. *Certolizumab pegol. *Etanercept. *Golimumab. *Infliximab. References[edit]. *^ a b c .mw-parser-output ...
Virus del Zika - Viquipèdia, l'enciclopèdia lliure
Saiz, JC; Martín-Acebes, MA «Zika virus: a race in search for antivirals» (en anglès). Antimicrob Agents Chemother., 2017; Mar ... Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study (Z001)» (en anglès), ClinicalTrials.gov/U ... fet que podria desencadenar una resposta defensiva del cos contra el virus i també contra el seu propi sistema del complement, ... Rossignol, JF «Nitazoxanide: A first-in-class broad-spectrum antiviral agent» (en anglès). Antiviral Res, 2014 Oct; 110, pp: 94 ...
Hepatitis B
Complement-component studies". The New England Journal of Medicine. 285 (4): 185-9. doi:10.1056/NEJM197107222850401. PMID ... It stimulates genes that promote cell growth and inactivates growth regulating molecules.[44] ... In 2015 the World Health Organization recommended tenofovir or entecavir as first-line agents.[82] Those with current cirrhosis ...
Whooping cough
Efforts to develop an inactivated whole-cell vaccine began soon after B. pertussis was cultured that year. In the 1920s, Louis ... complement fixation test).[35] The bacteria can be recovered from the person only during the first three weeks of illness, ... may be used in those with allergies to first-line agents or in infants who have a risk of pyloric stenosis from macrolides.[6] ...
Apoptosis
MAC (not to be confused with the Membrane Attack Complex formed by complement activation, also commonly denoted as MAC), also ... are mutated or inactivated in diseased cells, and further genes (such as bcl-2) also modify their expression in tumors. Some ... The addition of agents such as Herceptin, Iressa, or Gleevec works to stop cells from cycling and causes apoptosis activation ... "Human Papillomavirus Type 16 E6 and HPV-16 E6/E7 Sensitize Human Keratinocytes to Apoptosis Induced by Chemotherapeutic Agents ...
Hemolytic-uremic syndrome
Shiga-toxin directly activates the alternative complement pathway and also interferes with complement regulation by binding to ... A variety of viruses have also been implicated as a causative agent. It is now the most common cause of acquired acute renal ... the binding action of Shiga-toxin inactivates a metalloproteinase called ADAMTS13, the deficiency of which causes the closely ... complement factor H, an inhibitor of the complement cascade. Shiga-toxin causes complement-mediated platelet, leukocyte, and ...
DNA methylation
If the mismatch is not repaired and the cell enters the cell cycle the strand carrying the T will be complemented by an A in ... This may serve as a novel therapeutic agent to treat atherosclerosis, although no human studies have been conducted thus far.[ ... state that definitely inactivates transcription. In particular, DNA methylation appears critical for the maintenance of mono- ... An ex vivo experiment using the demethylating agent Decitabine (5-aza-2 -deoxycytidine) was shown to induce MCT3 expression in ...
Respiratory syncytial virus
They named the virus CCA (Chimpanzee Coryza Agent),[45] although it was later realized that the chimpanzees caught the ... Attempts to develop an RSV vaccine began in the 1960s with a formalin-inactivated vaccine that was developed for use in infants ... During replication of the negative-sense viral genome, RNA-dependent RNA polymerase synthesizes a positive-sense complement ... Blount RE, Morris JA, Savage RE (July 1956). "Recovery of cytopathogenic agent from chimpanzees with coryza". Proceedings of ...
Pepsin
Samuels TL, Johnston N (Nov 2009). "Pepsin as a causal agent of inflammation during nonacidic reflux". Otolaryngology-Head and ... 2-phenylethane reversibly inactivates pepsin at pH 5, a reaction which is accelerated by the presence of Cu(II).[31] ... because they are not able to bind complement, which could lyse the cells. F(ab')2, and to a greater extent Fab, fragments allow ... however pepsin is not fully denatured or irreversibly inactivated until pH 8.0.[13] Therefore, pepsin in solution of up to pH ...
Avian orthoreovirus
Infectious agents, which increase the pathogenicity of reovirus in the joints of chicken, include Mycoplasma synoviae, ... Vaccines are available (ATCvet codes: QI01AA04 (WHO) for the inactivated vaccine, QI01AD10 (WHO) for the live vaccine, plus ... They can be confirmed using virus isolation, complement fixation, ELISA, immunodiffusion or histopathology (following ... Van der Heide, L.; Lutticken, D.; Horzinek, M. (1981). "Isolation of avian reovirus as a possible etiologic agent of ...
Mitogen-activated protein kinase
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (Dec 2002). "The protein kinase complement of the human genome". ... some tyrosine phosphatases are also involved in inactivating MAP kinases (e.g. the phosphatases HePTP, STEP and PTPRR in ... it is natural that ERK1/2 inhibitors would represent a desirable class of antineoplastic agents. Indeed, many of the proto- ... are successful antineoplastic agents against various types of cancer.[39][40] ...
Lipopolysaccharide
... and as a result are able to increase their resistance to complement-mediated killing [33] or even down-regulate complement ... Being of crucial importance to Gram-negative bacteria, these molecules make candidate targets for new antimicrobial agents. ... Neutrophils, macrophages and dendritic cells produce this lipase, acyloxyacyl hydrolase (AOAH), which inactivates LPS by ... Pronounced complement activation can also be observed later in the course as the bacteria multiply in the blood.[43] High ...
Orthohantavirus
However, whole virus inactivated bivalent vaccines against Hantaan virus and Seoul virus are available in China and South Korea ... Integrins are considered to be the main receptors for hantaviruses in vitro but complement decay-accelerating factor (DAF) and ... Agents of HPS found in South America include the Andes virus (also called Oran, Castelo de Sonhos - Portuguese for "Castle of ... globular heads of complement C1q receptor (gC1qR) have mediated attachment in cultured cells too. Entry may proceed through a ...
Buffalo Soldier
The 28th Cavalry was inactivated at Assi-Okba, Algeria, in April 1944 in North Africa, and marked the end of the regiment. ... Due in part to the heightened hysteria caused by World War I, allegations surfaced that German agents fomented this violence ... reducing the black complement to two regiments (the 24th and 25th (Colored) Infantry). The 38th and 41st were reorganized as ... could not substantiate accusations of militant German agents in the Mexican border community and instead traced the origins of ...
Reverse transcription polymerase chain reaction
When the Scorpion extension binds to its complement on the amplicon, the Scorpion structure opens, prevents FRET, and enables ... Next, place the PCR tube into a thermal cycler for one cycle wherein annealing, extending, and inactivating of reverse ... as simple as quantification of yeast cells in wine to more complex uses as diagnostic tools for detecting infectious agents ... The second cycle is the initial denaturation wherein reverse transcriptase is inactivated. The remaining 40-50 cycles are the ...
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function - Full Text View - ClinicalTrials.gov
Complement C1 Inhibitor Protein. Complement Inactivating Agents. Immunosuppressive Agents. Immunologic Factors. Physiological ... The complement cascade in kidney disease: from sideline to center stage. Am J Kidney Dis. 2013 Sep;62(3):604-14. doi: 10.1053/j ... Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur J Immunol. 2010 Mar;40(3):668-70. doi: ... Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol. 2004 Nov;41(11):1089-98. Review. ...
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers - Full Text View -...
Complement C3. Complement Inactivating Agents. Immunologic Factors. Physiological Effects of Drugs. Immunosuppressive Agents. ... Complement protein C3 plasma levels [ Time Frame: Up to 14 days after treatment. ]. *Complement protein C4 plasma levels [ Time ... complement inhibition. C3 complement inhibitor. AMY-101. Compstatin Cp40. Paroxysmal Nocturnal Hemoglobinuria (PNH). C3 ... AMY-101 is a selective inhibitor of complement activation in humans and in NHP. It binds to the complement component C3, the ...
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic...
Complement Inactivating Agents. Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. To Top ... Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic ... Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic ... ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement ...
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia - Full Text View - ClinicalTrials.gov
Complement Inactivating Agents. Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. To Top ... The complement system in COVID-19: friend and foe? JCI Insight. 2020 Aug 6;5(15). pii: 140711. doi: 10.1172/jci.insight.140711 ... Current treatment with a complement inhibitor or. *Intravenous immunoglobulin (IVIg) within 4 weeks prior to randomization on ...
Complement as a target in COVID-19?
Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients. ... Complement Activation* / drug effects * Complement Inactivating Agents / therapeutic use * Complement System Proteins / ... Complement as a target in COVID-19? Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23. ... Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients. ...
Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
... is widely regarded as an archetypal complement-mediated disorder that has propelled complement drug discovery in recent decades ... Its pathology is driven by chronic complement dysregulation resulting from the lack of the glycosyl phosphatidyl inositol- ... Complement Inactivating Agents / therapeutic use* * Complement System Proteins / physiology* * Hemoglobinuria, Paroxysmal / ... This complement imbalance fuels persistent C3 activation on affected erythrocytes, which culminates in chronic complement- ...
Meningococcemia Medication: Antimicrobial agents, Inotropic Agents, Diuretics, Osmotic Agents, Diuretics, Loop, Corticosteroids...
Vaccines, Inactivated, Bacterial. Class Summary. These agents may be used to prevent and control outbreaks of serogroup C ... Jarva H, Ram S, Vogel U, Blom AM, Meri S. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J ... Diuretics, Osmotic Agents. Class Summary. These agents are used to control ICP during elective intubation. Osmotic diuretics ... Inotropic Agents. Class Summary. These agents are used to support circulation in patients with shock. ...
Skin Injuries Reduce Survival and Modulate Corticosterone, C-Reactive Protein, Complement Component 3, IgM, and Prostaglandin...
Complement component 3 (C3) is a key component responsible for inactivating many antigens, particularly infectious agents [15 ... IgM antibodies and the C3b inactivator cleaved third component of complement in macrophage phagocytosis," Agents and Actions, ... Complement component 3 (C3) plays a central role in the activation of complement system [15]. People with C3 deficiency are ... Agents inhibiting these responses may prove to be therapeutic for radiation combined injury and improve chances for survival. ...
Which medications in the drug class Immunomodulatory Agents are used in the treatment of Guillain-Barre Syndrome?
The product is treated with solvents and detergents to inactivate any blood-borne virus. IVIG may work via several mechanisms, ... An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011 Jun. 16(2):84- ... Immunomodulatory Agents. These medications are used to improve the clinical and immunologic aspects of GBS. They may decrease ... Which medications in the drug class Immunomodulatory Agents are used in the treatment of Guillain-Barre Syndrome?. Updated: Jun ...
BacMam - Wikipedia
Furthermore, BacMam viruses are inactivated by human complement, which reduces risk to researchers. Lastly, viruses used in the ... Baculoviruses are Risk Group 1 agents that have been widely used for over 25 years for insect cell protein production ... "Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system ...
APPENDIX C Glossary | Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality | The National...
Inactivate.. To make biologically inactive, as viruses or bacteria, toxins, or serum complement, by any of various means, such ... 1. The agent must be shown to be present in every case of the disease by isolation in pure culture. ... Inactivated polio vaccine (IPV).. A sterile suspension of three types of inactivated polioviruses. The viruses are grown ... The infectious agent may circulate in the blood for long periods of time (months or years) and is characteristically ...
Occupational Asthma
Atopy and smoking are not risk factors for OA caused by LMW agents as they are for OA caused by HMW agents. Some of the better- ... They can also inhibit the neutral endopeptidases that normally inactivate these substances. This affects a variety of cells in ... Isocyanates can block beta 2-adrenergic receptors, and high concentrations of plicatic acid can activate complement. Moreover, ... Agents associated with an immunologic cause can be further divided into HMW agents, usually allergens such as proteins from ...
C4bp complement protein - Semantic Scholar
It binds as a cofactor to COMPLEMENT FACTOR I which then hydrolyzes the COMPLEMENT C4B in the CLASSICAL PATHWAY C3 CONVERTASE ( ... A serum protein that regulates the CLASSICAL COMPLEMENT ACTIVATION PATHWAY. ... C4bp complement protein. physiological aspects. agonists. Carrier Proteins. chemical synthesis. Complement Inactivating Agents ... C4bp complement protein. Known as: C4bC3bINA Cofactor, Complement C3b C4b Inactivator Cofactor, Protein, Complement C4b-Binding ...
Mutation of the priA Gene of Neisseria gonorrhoeae Affects DNA Transformation and DNA Repair | Journal of Bacteriology
These phenotypes were complemented by supplying a functional copy of priA elsewhere in the chromosome. The N. gonorrhoeae priA ... The priA mutant was also more sensitive to the oxidative damaging agents H2O2 and cumene hydroperoxide compared to the parental ... Insertionally inactivated and inducible recA alleles for use in Neisseria. Gene188:215-220. ... 4A). This repair defect was fully restored in the priA complement strain. We also tested whether priA is involved in the repair ...
Critical Importance of In Vivo Amoxicillin and Cefotaxime Concentrations for Synergy in Treatment of Experimental Enterococcus...
... complement-inactivated rabbit plasma. The in vitro bactericidal killing rates were determined by the macrodilution method in ... Antimicrobial Agents and Chemotherapy Feb 1998, 42 (2) 468-470; DOI: 10.1128/AAC.42.2.468 ... Antimicrobial Agents and Chemotherapy Feb 1998, 42 (2) 468-470; DOI: 10.1128/AAC.42.2.468 ... B4 Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996 22 American Society ...
Patente US5348876 - IgG3 antibodies with shortened hinge region and a complement activation test - Google Patentes
... followed by assay of components of the complement complex thereby formed; whereby the extent and nature of complement ... Also described is a method for assaying an antibody against a specific antigen or hapten for its effectiveness in complement ... immobilized antigen or hapten to form an immobilized antibody/antigen or hapten complex which is then contacted with complement ... using an inactivated sample of the serum used as source of the antibody and/or complement. Non-specific binding can be reduced ...
Patent US6761893 - Modified vaccinia ankara virus variant - Google Patents
"Vaccination" means that an organism is challenged with an infectious agent, e.g., an attenuated or inactivated form of the ... comprising small peptides and complement factors. ... The organism, thus, is immunized against the agent/protein ... Preferably, the virus is inactivated by β-propriolacton. According to this embodiment of the invention, the inactivated virus ... Thus, a second infection with the same or a very similar infectious agent causes much milder symptoms or no symptoms at all, ...
DailyMed - CARIMUNE NANOFILTERED- human immunoglobulin g injection, powder, lyophilized, for solution
... considered as a model for the vCJD and CJD agents.18 To complement the existing virus elimination / inactivation mechanism in ... PRV and the two model viruses for HCV, BVDV and SFV, were inactivated within 1/10, and HIV within 1/2 of the incubation time ( ... agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior ... Because Carimune® NF is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the ...
US6369048B1 - Methods and compositions for inactivating viruses
- Google Patents
... including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed. ... Methods and compositions for selectively inactivating viruses in biological compositions, ... The solvent-detergent mixture and the selective inactivating agents complement each other and can be used simultaneously. The ... b) contacting the composition with an inactivating agent under viral inactivating conditions, wherein said inactivating agent ...
Gambetta, K. E.<...
List of MeSH codes (D27) - Wikipedia
... immunosuppressive agents MeSH D27.505.696.477.656.500 - complement inactivating agents MeSH D27.505.696.477.656.750 - ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ... tranquilizing agents MeSH D27.505.696.277.950.015 - anti-anxiety agents MeSH D27.505.696.277.950.025 - antimanic agents MeSH ...
Serum for Cell and Tissue Culture: Frequently Asked Questions (FAQs) | Sigma-Aldrich
Why (and how) is some serum heat-inactivated?. Complement proteins naturally occurring in mammalian sera mediate cytolytic ... serum has been exposed to a Cobalt-60 source at a 25-35 kGy dose to inactive viruses and other adventitious microbial agents ( ... Heat-inactivation destroys the activity of complement in serum. This method is therefore recommended for immunological ...
Patent US5419759 - Apparatus and methods for treatment of HIV infections and AIDS - Google Patents
The preferred organic agent is diethyl ether which is used in an amount and over a period of time sufficient to kill the ... The uninfected components are returned to the patient and the infected components are treated with organic agents. ... complement, clotting factors, enzymes, and blood factors; said organic agents being otherwise proportionately too harmful to be ... To inactivate the virus a dose higher than 2.5 105 rad would be needed. It was also found that LAV reverse transcriptase ...
Find Research outputs
- the University of Bath's research portal
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering | Haematologica
... high levels of cell killing largely required active complement, since CDC was almost absent in heat-inactivated NHS, NHS ... whereas the single agents induced only 5% and 10% lysis respectively. Despite high single agent activity of Hx-CD37 and Hx-CD20 ... Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. Mol Immunol. 2015;67(2, ... Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement- ...
An in vitro study on the mechanism of innate immunity in Cryptobia-resistant brook charr ( Salvelinus fontinalis) against...
However, the parasite was not lysed if the plasma was heat-inactivate ... However, the parasite was not lysed if the plasma was heat-inactivated at 37°C for 2 h or after the addition of ... The alternative pathway of complement activation is the mechanism of innate immunity against C. salmositica. The present study ... Treatment of Cryptobia-resistant plasma with either ethylenebis(oxyethylenenitrilo)tetraacetic acid, a Ca2+-chelating agent, or ...
Acute Transverse Myelitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Body defense mechanism and immunity
The term immunity refers to the bodys specific protective response to an invading foreign agent or organism. The human body ... Antibodies• The antibodies can inactivate the invading agent in one of the several ways, as follows:1. Agglutination: in which ... are known as complement.• Complement has three major physiological functions: a. defending the body against bacterial infection ... agents and thereby cause rupture of the agent. Page 21 ... Complement system• Circulatory plasma proteins which are made ...
DNA Repair Protein Complementing XP-G Cells (ERCC5) Antikörper
introduced a point mutation into the XPG gene which inactivates the nuclease (zeige DCLRE1C Antikörper) catalytic site but ... XPG mRNA expression was not predictive of trabectedin efficacy as single agent in hormone-positive, HER-2 (zeige ERBB2 ... Weitere Produktkategorien zu DNA Repair Protein Complementing XP-G Cells Antikörper * 91 anti-DNA Repair Protein Complementing ... anti-DNA Repair Protein Complementing XP-G Cells (ERCC5) Antikörper. Bezeichnung:. anti-DNA Repair Protein Complementing XP-G ...
InhibitorsProteinsInhibitionPathwayMembrane AttackAntibodiesEculizumabTherapeuticReceptorsParoxysmal Nocturnal HemoVaccinesHeat-inactivatedInsertionally inactivatedMutationsInhibitsProteinRole of complementReperfusion injuryStrainsVirusesAntigensInactivationAntibodyImmune responseDiseasesHumansSubstancesCellsMolecularSoluble complementSystemStreptococcusDysregulationActivation of the complementPathwaysInfectionDeficiencyGeneRegulatoryTissueImmunoglobulinInflammatoryEnzymesPotentHuman serumFunctionalBacterialMechanismTargetingKidney
Inhibitors14
- Phosphoethanolamine residues on the lipid A moiety of Neisseria gonorrhoeae lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing. (semanticscholar.org)
- Therefore, the possibility that complement inhibitors may have a salutary effect in humans with aspiration-induced lung injury should be investigated. (elsevier.com)
- This review summarizes the involvement of the terminal effector agents of the complement system in these diseases and provides an overview of inhibitors for complement components C5, C5a, C5aR1, and MAC that are currently in clinical development. (cdc.gov)
- The chapters in this book cover a wide range of topics related to the development of complement therapeutics, ranging from the molecular and functional description of complement targets to the presentation of novel inhibitors, improved treatment strategies as well as examples of disease models and clinical applications. (missouri.edu)
- ACE inhibitors of the urine using agents that metabolizes intracellular and aP-1 Platelets adhere to reduce mortality. (imagenenaccion.org)
- ACE inhibitors of the urine using agents that metabolizes intracellular and aP-1. (imagenenaccion.org)
- Given the role of complement in disease, there is a requirement for inhibitors to control the initiating proteases. (edu.au)
- We reviewed previously reported cases and discussed diagnosis and treatment strategies, including novel complement inhibitors, as potential future therapy. (elsevier.com)
- In addition, newer drugs including antisense molecule, tumor necrosis factor alpha receptor blocker and complement inhibitors are currently under investigation to confirm their effectiveness. (elsevier.com)
- The plasma protein inhibitors are factor H and C4-binding protein, and the regulatory membrane proteins located on cell surfaces are complement receptors 1 (CR1), decay-accelerating factor (DAF), and membrane cofactor protein (MCP). (justia.com)
- To date, there are no inhibitors of complement activation used in the clinic, though certain candidates for clinical use exist, specifically, a recombinant form of complement receptor 1 known as soluble complement receptor 1 (sCR1) and a humanized monoclonal anti-05 antibody (5G1.1-scFv). (justia.com)
- Thus, up to 7 % of lung adenocarcinomas that have acquired somatic mutations that inactivate ATM may respond extremely well to radiotherapy, while lung cancers that express functional ATM are anticipated to be radiosensitized by ATM kinase inhibitors. (biomedcentral.com)
- ATR kinase inhibitors also kill cell lines with mutations in either ATM or TP53 with greater efficacy than complemented control cell lines. (biomedcentral.com)
- Neisseria meningitidis recruits host human complement inhibitors to its surface to down-regulate complement activation and enhance survival in blood. (ox.ac.uk)
Proteins12
- Herein, the IL-6-induced stress proteins including C-reactive protein (CRP), complement 3 (C3), immunoglobulin M (IgM), and prostaglandin E 2 (PGE 2 ) were evaluated after skin injuries given following a mixed radiation environment that might be found after a nuclear incident. (hindawi.com)
- Agents associated with an immunologic cause can be further divided into HMW agents, usually allergens such as proteins from laboratory animals, flour, or plants, or LMW agents, usually chemicals such as isocyanates, biocides, or drugs. (clevelandclinicmeded.com)
- There are currently known 4 counter-regulatory proteins (Factor H, Factor I, MCP, thrombomodulin) in which inactivating mutations lead to excessive complement activity. (omicsonline.org)
- There are 2 proteins (Factor B, C3) that are integral complement component in which gain of function mutations lead to excessive complement activity. (omicsonline.org)
- Mutations in genes encoding complement regulatory proteins have been reported both in familial and in nonfamilial cases, mainly in idiopathic forms ( 5 , 6 ) but also in cases of pregnancy-associated ( 5 ) and postpartum HUS ( 8 , 9 ), ticlopidine-induced HUS ( 5 ), and postinfectious HUS ( Neisseria meningitidis ) ( 10 ). (asnjournals.org)
- By use of purified proteins and cell-expression system, they explored thrombomodulin's role in regulation of the complement system and characterized the mechanisms. (medpagetoday.com)
- In vivo, regulation of complement at the C3 and C5 activation steps is provided by both plasma and membrane proteins. (justia.com)
- These proteins inhibit the C3 and C5 convertases (multi-subunit proteases), by promoting dissociation of the multisubunit complexes and/or by inactivating the complexes through proteolysis (catalyzed by factor I). Several pharmacological agents that regulate or modulate complement activity have been identified by in vitro assay, but most have been shown in vivo to be of low activity or toxic. (justia.com)
- Immunologic characteristics include high ANA and anti-dsDNA, presence of anti-Smith (anti-Sm) proteins, antiphospholipid antibodies (APAs), low complement, and direct Coombs test. (uspharmacist.com)
- The immune system identifies invading "foreign" compositions and agents primarily by identifying proteins and other large molecules which are not normally present in the individual. (justia.com)
- There are several vaccine strategies for presenting pathogen proteins which include presenting the protein as part of a non-infective or less infective agent or as a discreet protein composition. (justia.com)
- One strategy for immunizing against infection uses killed or inactivated vaccines to present pathogen proteins to an individual's immune system. (justia.com)
Inhibition12
- IVIG may work via several mechanisms, including the blockage of macrophage receptors, the inhibition of antibody production, the inhibition of complement binding, and the neutralization of pathologic antibodies. (medscape.com)
- It was postulated that inhibition or depletion of complement attenuates aspiration-induced lung injury. (elsevier.com)
- The effect of complement inhibition by recombinant human soluble complement receptor type 1 (n = 8) or complement depletion by cobra venom factor (n = 7) on lung injury was evaluated. (elsevier.com)
- The patient developed a subsequent flare of her systemic lupus erythematosus, potentially indicating that complement inhibition by eculizumab is not effective in preventing lupus flares. (elsevier.com)
- Taken together, we describe a unique case of life-threatening and difficult-to-treat CAPS with a good clinical response after terminal complement complex inhibition with eculizumab. (elsevier.com)
- The paradigm of safe and efficacious terminal complement pathway inhibition has been demonstrated by the approval of eculizumab in paroxysmal nocturnal hematuria. (cdc.gov)
- Mechanistic studies indicate that eqSCIN blocks equine complement activation by specific inhibition of the C3 convertase enzyme (C3bBb). (wur.nl)
- We reported inhibition of growth of primary rat mammary carcinomas after infusions of tumor-bearer plasma absorbed with Protein A-Sepharose or inactivated CNBr Sepharose. (aacrjournals.org)
- The results are consistent with a role for the alternative pathway of complement in the inhibition of growth of rat primary mammary carcinomas observed after treatment with absorbed sera. (aacrjournals.org)
- ATR kinase inhibition sensitizes cells to agents that induce replication stress and selectively kills cells with ATM and TP53 mutations. (biomedcentral.com)
- Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents. (abcam.com)
- Structural basis for therapeutic inhibition of complement C5. (ox.ac.uk)
Pathway13
- Activation of the classical complement pathway [ Time Frame: Up to 14 days after treatment. (clinicaltrials.gov)
- Here, we review the current state of complement therapeutics with a focus on the clinical development of C3-targeted and alternative pathway-directed drug candidates for the treatment of PNH. (nih.gov)
- The alternative pathway of complement activation is the mechanism of innate immunity against C. salmositica . (springer.com)
- The present study also shows that there is functional heterogeneity amongst the complement components activated via the alternative pathway within a species (brook charr) and between species (brook charr and goldfish) of fishes. (springer.com)
- Infection, surgery, autoimmune disease and pregnancy are the major activators of the complement pathway. (omicsonline.org)
- This leaves the proximal complement pathway intact while inactivating the terminal part of the pathway, thereby eliminating the production of the membrane attack complex. (omicsonline.org)
- As other immunosuppressive agents were considered dangerous because of the risk of infections in the face of severe hypogammaglobulinemia, we administered eculizumab, an inhibitor of the terminal complement pathway, which led to a persistent control of her disease. (elsevier.com)
- Complement deposition assays revealed that gigastasin is an effective inhibitor of complement activation in vivo, especially for activation via the lectin pathway. (edu.au)
- The first identified genetic cause was deficiency in complement factor H (CFH) ( 8 , 11 - 14 ), a plasma glycoprotein that plays an important role in the regulation of the alternative pathway of complement ( 15 ) by controlling both spontaneous fluid phase C3 activation and its deposition on host cells. (asnjournals.org)
- These results suggested that activation of the alternative pathway of complement might be involved in the observed antitumor effects. (aacrjournals.org)
- Ethylenebis(oxyethylenenitrilo)]tetraacetic acid, by chelating calcium but not magnesium, permits activation of the alternative pathway but inhibits activation of the classical complement pathway. (aacrjournals.org)
- Activation of C3 by complement pathway C3 convertases and its subsequent attachment to target surface leads to assembly of the membrane attack complex and ultimately to damage or lysis of the target cells. (justia.com)
- An important gene associated with C1 Inhibitor Deficiency is SERPING1 (Serpin Family G Member 1), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Immune response Lectin induced complement pathway . (malacards.org)
Membrane Attack1
- Complement-mediated tissue injuries are directly mediated by the membrane attack complex, and indirectly by the generation of C3a and C5a. (justia.com)
Antibodies7
- Antibodies specific for CD37, a target that is abundantly expressed on healthy and malignant B cells, are generally poor inducers of complement-dependent cytotoxicity. (haematologica.org)
- Here we demonstrate that introduction of the hexamerization-enhancing mutation E430G in CD37-specific antibodies facilitates highly potent complement-dependent cytotoxicity in chronic lymphocytic leukemia cells ex vivo . (haematologica.org)
- Strikingly, we observed that combinations of hexamerization-enhanced CD20 and CD37 antibodies cooperated in C1q binding and induced superior and synergistic complement-dependent cytotoxicity in patient-derived cancer cells compared to the single agents. (haematologica.org)
- Conclusion Explain why antibodies allow scientists to target and identify specific disease agents. (studymode.com)
- Antibodies allow scientists to target and identify specific disease agents because they bind to antigens to counteract them. (studymode.com)
- Acquired auto-antibodies resulting in excessive activity include: Inactivating Factor H antibodies, C3 nephritic factor stabilizing C3 convertase, and C4 nephritic factor stabilizing C4 convertase. (omicsonline.org)
- correlation with serum-neutralizing and complement-fixing antibodies. (mdedge.com)
Eculizumab2
- Eculizumab is a humanized anti-complement monoclonal antibody that has been utilized in the treatment of complements mediated diseases, including: Paroxysmal Nocturnal Hemoglobinuria (PNH), aHUS, C3G, and catastrophic anti-phospholipid syndrome. (omicsonline.org)
- Interestingly, eculizumab therapy was associatedwith a further decline of complement C3 and C4 serumlevels. (elsevier.com)
Therapeutic5
- Agents inhibiting these responses may prove to be therapeutic for RCI and improve related survival. (hindawi.com)
- The recent development of therapeutic anti-complement antibody preparations has enabled the clinician to capitalize on these scientific advances by treating these disorders in a targeted fashion. (omicsonline.org)
- Although the complement cascade with its close to 50 extracellular protein targets has long been recognized as an attractive system for therapeutic modulation, the past few years have seen a particularly strong boost in interest. (missouri.edu)
- Since thrombomudulin simultaneously suppresses the complement and coagulation systems, its administration may have therapeutic value for some patients with the atypical hemolytic-uremic syndrome. (medpagetoday.com)
- The choice of MV as a therapeutic agent for myeloma was not happenstance, but rather the result of several years of thoughtful biological experimentation and rational virus engineering. (joannenova.com.au)
Receptors2
- It is produced by the liver and binds to phosphocholine on microbes assisting in complement binding to foreign and damaged cells and enhancing phagocytosis by macrophages expressing CRP receptors. (hindawi.com)
- They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. (nih.gov)
Paroxysmal Nocturnal Hemo1
- Paroxysmal nocturnal hemoglobinuria (PNH) is widely regarded as an archetypal complement-mediated disorder that has propelled complement drug discovery in recent decades. (nih.gov)
Vaccines6
- We have investigated whether such complement inhibitor binding occurs after vaccination with native outer membrane vesicles (nOMVs), and limits immunogenicity of such vaccines. (ox.ac.uk)
- Vaccines being developed include live attenuated, subunit, particle based and live vectored agents. (bmj.com)
- In the search for safe and effective vaccines for immunizing individuals against infective pathogenic agents such as viruses, bacteria, and infective eukaryotic organisms, several strategies have been employed thus far. (justia.com)
- In such vaccines, the pathogen is either killed or otherwise inactivated using means such as, for example, heat or chemicals. (justia.com)
- Killed or inactivated pathogen vaccines provide protection by directly generating T-helper and humoral immune responses against the pathogenic immunogens. (justia.com)
- Attenuated vaccines are often produced by passaging several generations of the pathogen through a permissive host until the progeny agents are no longer virulent. (justia.com)
Heat-inactivated2
- However, the parasite was not lysed if the plasma was heat-inactivated at 37°C for 2 h or after the addition of ethylenediaminetetraacetic acid (EDTA) to chelate the free Mg 2+ ions. (springer.com)
- Heat-inactivation (56 °C, 1 hr) destroyed the killing effect of immune serum but the borreliacidal activity of heat-inactivated immune serum could be restored by the addition of pre-immune serum. (uri.edu)
Insertionally inactivated2
- To investigate the role of PriA in recombination and repair in Neisseria gonorrhoeae , we identified, cloned, and insertionally inactivated the gonococcal priA homologue. (asm.org)
- As Southern hybridization analysis of different clinical isolates of D. nodosus indicated that the fur gene was present in all of these strains, the fur gene was insertionally inactivated to determine its functional role. (asm.org)
Mutations3
- About half of patients with atypical presentation have mutations in genes involved in the regulation of the complement system, the authors said. (medpagetoday.com)
- By 1998, Milstein, Cristina Rada, and Neuberger noticed that certain genetic models could separate intronic mutations into discrete phases: an agent that caused G:C mutations and one that caused A:T mutations. (jci.org)
- Thus, up to 7 % of lung adenocarcinomas that have acquired somatic mutations that inactivate ATM may respond to single agent therapy with an ATR kinase inhibitor. (biomedcentral.com)
Inhibits3
- One arm 'targets' the drug to the site of tissue damage, thus concentrating the therapy exactly where it is most needed, and the second arm (CD59) inhibits a specific part of the complement system that would drive further damage if left unchecked. (labroots.com)
- Whereas SCIN-A from human S. aureus isolates exclusively inhibits human complement, eqSCIN represents the first animal-adapted SCIN variant that functions in a broader range of hosts (horses, humans, and pigs). (wur.nl)
- describes the use of a phage-displayed combinatorial random peptide library to identify a 27-residue peptide that binds to C3 and inhibits complement activation. (justia.com)
Protein16
- Complement protein C3 plasma levels [ Time Frame: Up to 14 days after treatment. (clinicaltrials.gov)
- Ionizing radiation perturbs hematopoiesis in bone marrow, which, in turn, depresses the innate immune responses against infectious agents, including production of immunoglobulins, and disturbs the inflammatory responses, including C-reactive protein (CRP), the components of complement, and the normal balance among the inflammatory and anti-inflammatory cytokines and chemokines. (hindawi.com)
- Baculoviruses are Risk Group 1 agents that have been widely used for over 25 years for insect cell protein production applications. (wikipedia.org)
- Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity. (semanticscholar.org)
- Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. (semanticscholar.org)
- Auf www.antikoerper-online.de finden Sie aktuell 91 DNA Repair Protein Complementing XP-G Cells (ERCC5) Antikörper von 19 unterschiedlichen Herstellern. (antikoerper-online.de)
- Zusätzlich bieten wir Ihnen DNA Repair Protein Complementing XP-G Cells Kits (12) und DNA Repair Protein Complementing XP-G Cells Proteine (5) und viele weitere Produktgruppen zu diesem Protein an. (antikoerper-online.de)
- Insgesamt sind aktuell 115 DNA Repair Protein Complementing XP-G Cells Produkte verfügbar. (antikoerper-online.de)
- Within this phage, we discovered a novel variant of staphylococcal complement inhibitor (SCIN), a secreted protein that interferes with activation of the human complement system, an important line of host defense. (wur.nl)
- The complement regulatory protein decay-accelerating factor (DAF or CD55) was induced following PGE 2 treatment of LS174T colon cancer cells. (elsevier.com)
- Sera in the presence or absence of chelating agent were absorbed with Protein A-Sepharose twice at room temperature. (aacrjournals.org)
- Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. (justia.com)
- In particular, this invention provides peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation. (justia.com)
- In this report, we identify a protein from the Trypanosoma cruzi (the protozoan agent of Chagas disease) endoplasmic reticulum (ER), as responsible for, at least an important part of the antitumor effect of this infection. (biomedcentral.com)
- nOMVs unable to bind human complement factor H (hfH) were generated by additional deletions of the genes encoding factor H binding protein (fHbp) and neisserial surface protein A (NspA) (nOMVdis). (ox.ac.uk)
- If this switch is activated with a special agent, stem cells in the bone marrow, from which all blood-circulating immune cells originate, produce a colored fluorescent protein. (uni-bonn.de)
Role of complement3
- Objectives: To examine the role of complement in the development of acid aspiration-induced lung injury in the rat. (elsevier.com)
- T he role of complement activation as a primary etiology and a secondary exacerbater of kidney disease have long been known. (omicsonline.org)
- Recent advances in complement physiology have elucidated the central role of complement dysregulation as the root cause of hematologic, glomerular and systemic diseases. (omicsonline.org)
Reperfusion injury1
- As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been identified as contributor to a large number of disorders including ocular, cardiovascular, metabolic, autoimmune, and inflammatory diseases as well as in ischemia/reperfusion injury, cancer and sepsis. (missouri.edu)
Strains5
- This review highlights the differences in the resistance or susceptibility of different strains of coronaviruses, or similar viruses, to these antimicrobial agents. (frontiersin.org)
- In addition, aggregation of CBP + /PA − strains was drastically reduced when serum complement was inactivated. (asm.org)
- three foot-and-mouth disease virus type a isolates recovered from field outbreaks in the department of san martin, peru, during the period 1975 to 1981 were compared with each other, and the south american vaccine strains a24 and a27, by complement fixation (cf), virus neutralization (vn) and polyacrylamide gel electrophoresis (page). (liverpool.ac.uk)
- complement fixation and vn tests gave comparable results distinguishing the field isolates from each other and from the vaccine strains. (liverpool.ac.uk)
- O-antigen-negative strains were found to be sensitive to complement and cationic peptides, but they displayed significant resistance to bile salts and short-chain organic acids. (asm.org)
Viruses6
- 18 To complement the existing virus elimination / inactivation mechanism in the Carimune ® NF manufacturing process, nanofiltration (removing viruses via size-exclusion) was introduced as an additional virus removal step into the manufacturing process. (nih.gov)
- Treatment with pepsin at pH 4 rapidly inactivates enveloped viruses. (nih.gov)
- Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed. (google.com)
- This invention relates to methods and compositions for inactivating viruses in biological compositions. (google.com)
- Gamma-irradiated serum has been exposed to a Cobalt-60 source at a 25-35 kGy dose to inactive viruses and other adventitious microbial agents (such as mycoplasmas). (sigmaaldrich.com)
- Interestingly, A. aegypti is also naturally infected with insect-only viruses, such as cell-fusing agent virus. (asm.org)
Antigens1
- Complement component 3 (C3) is a key component responsible for inactivating many antigens, particularly infectious agents [ 15 ]. (hindawi.com)
Inactivation3
- Yersinia enterocolitica YadA mediates complement evasion by recruitment and inactivation of C3 products. (semanticscholar.org)
- In vitro thrombomodulin binds to complement factor C3b (a promoter of complement activation and opsonization) and negatively regulates complement by accelerating factor I-mediated inactivation of C3b, the authors said. (medpagetoday.com)
- Cultured cells expressing thrombomodulin variants had a diminished capacity to inactivate C3b and to promote inactivation of the anaphylatoxins, thereby diminishing protection against activated complement. (medpagetoday.com)
Antibody4
- whereby the extent and nature of complement activation by the antibody in the sample may be determined. (google.es)
- We previously demonstrated that the natural process of antibody hexamer formation on targeted cells allows for optimal induction of complement-dependent cytotoxicity. (haematologica.org)
- In addition, complement contribution in rare kidney diseases, such as lupus nephritis, IgA nephropathy, atypical hemolytic uremic syndrome, C3 glomerulopathy, or antineutrophil cytoplasmic antibody-associated vasculitis has been demonstrated. (cdc.gov)
- Since vector competence appeared to be related to the activity of host antibody and complement in the tick midgut, I determined whether substances existed in I. scapularis that might inhibit or inactivate antibody or complement. (uri.edu)
Immune response6
- The infections, as well as brain inflammation, are the result of the body's natural disease-fighting immune response, called "complement. (labroots.com)
- Complement is crucial to the immune response, but dysregulation of the system causes inflammatory disease. (edu.au)
- DNA sequences both natural and synthetic encoding for the expression of immunogenic agents which are capable of causing an immune response in animals when fed in edible plants, plant tissues, or derived plant materials are constructed, and plants transformed for stable or transient expression in plant cells. (freepatentsonline.com)
- Vaccination and immunization generally refer to the introduction of a non-virulent agent against which an individual's immune system can initiate an immune response which will then be available to defend against challenge by a pathogen. (justia.com)
- The administration of killed or inactivated pathogen into an individual presents the pathogen to the individual's immune system in a noninfective form and the individual can thereby mount an immune response against it. (justia.com)
- By using an attenuated vaccine, an agent that displays limited infectivity may be employed to elicit an immune response against the pathogen. (justia.com)
Diseases3
- Despite its important role in pathogen elimination, priming and recruitment of myeloid cells from the immune system, as well as crosstalk with other physiological systems, inadvertent activation of the complement system can result in self-attack and overreaction in autoinflammatory diseases. (cdc.gov)
- Complement is implicated in several disease states, including various autoimmune diseases, and has been found to contribute to other clinical conditions such as adult respiratory syndrome, heart attack, rejection following xenotransplantation and burn injuries. (justia.com)
- Typically, this dope can be gained in Incline is a general fee in clinical pilot patients with diseases potentially receptive to design, regardless of the genus of litigation being con- these agents. (chesapeakehumane.org)
Humans1
- Unfortunately, this treatment approach could be harmful to humans because complement is essential for fighting infections-that's why this homing agent is so significant. (labroots.com)
Substances1
- Both of these substances have been shown to suppress complement activation in in vivo animal models (Kalli et al. (justia.com)
Cells6
- The preferred organic agent is diethyl ether which is used in an amount and over a period of time sufficient to kill the infected cells and the cell-free virus. (google.ca)
- Co- trimoxazole reduces the longest-acting agent that enter cells. (imagenenaccion.org)
- In a next step, the researchers inactivated the Cxcr4 gene function, leaving intact the molecular switch that helps them detect the immigrated immune cells. (uni-bonn.de)
- PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. (abcam.com)
- The cells may be contacted cells with a cell stimulating agent. (justia.com)
- were generated by immunising mice with inactivated B. melitensis or B. abortus cells. (biomedcentral.com)
Molecular2
- Two types of OA are distinguished by whether or not they appear after a latency period: (1) immunologic, characterized by a latency period, encompassing (a) that caused by high- (HMW) and low-molecular-weight (LMW) agents for which an immunologic (IgE) mechanism has been proven, and (b) that caused by agents (e.g., western red cedar) for which a specific immune mechanism has not been identified. (clevelandclinicmeded.com)
- To complement molecular detection systems for potential bioterror agents, as required by international biodefense regulations, sets of mAbs were generated by B cell hybridoma technology and used to develop immunological assays. (biomedcentral.com)
Soluble complement1
- In contrast, there was no effect of soluble complement receptor type 1 or of cobra venom factor on leukosequestration. (elsevier.com)
System11
- Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients. (nih.gov)
- Harris and colleagues have engineered a new duel "homing" agent that, when given to mice, inactivated the complement system in the brain, reduced inflammation, and aided recovery. (labroots.com)
- This drug therefore delivers therapy to where it is needed, freeing up the complement system to fight infection in the rest of the body. (labroots.com)
- The study, published in the Proceedings of the National Academy of Sciences , showed that when the homing agent was injected into mice immediately after traumatic brain injury, it specifically targeted the injured tissue, serving to inactivate the complement system and reduce inflammation and neuronal damage. (labroots.com)
- The complement system comprises the frontline of the innate immune system. (cdc.gov)
- The complement system in COVID-19: friend and foe? (wustl.edu)
- Complement System Activation in Cardiac and Skeletal Muscle Pathology: Friend or Foe? (missouri.edu)
- During the sepsis the coagulation cascade, the complement system and the activation system are activated, in different moments, and this contributes to the development of multiple organ failure. (unipa.it)
- We here show that this equine variant of SCIN, eqSCIN, is a potent blocker of equine complement system activation and subsequent phagocytosis of bacteria by phagocytes. (wur.nl)
- The complement system is the first line of immunological defense against foreign pathogens. (justia.com)
- By investigating several parameters in vitro, we could show that galU and R-LPS mutants were more sensitive to short-chain organic acids, cationic antimicrobial peptides, the complement system, and bile salts as well as other hydrophobic agents, indicating that their outer membrane no longer provides an effective barrier function. (asm.org)
Streptococcus1
- Streptococcus mutans , a major pathogen of dental caries, is considered one of the causative agents of infective endocarditis (IE). (asm.org)
Dysregulation1
- Its pathology is driven by chronic complement dysregulation resulting from the lack of the glycosyl phosphatidyl inositol-linked regulators DAF and CD59 on susceptible erythrocytes. (nih.gov)
Activation of the complement1
- This invention relates to activation of the complement cascade in the body. (justia.com)
Pathways3
- Complement is activated by three pathways: classical, lectin, and alternative. (edu.au)
- Ethylenedinitrilotetraacetic acid, by chelating calcium and magnesium, prevents activation of both the alternative and classical complement pathways. (aacrjournals.org)
- Complement component C3 plays a central role in activation of all three pathways. (justia.com)
Infection2
- Because the pathogen is killed or otherwise inactivated, there is little threat of infection. (justia.com)
- Brucella , a Gram-negative bacterium, is classified as a potential bioterrorism agent mainly due to the low dose needed to cause infection and the ability to transmit the bacteria via aerosols. (biomedcentral.com)
Deficiency1
- 12 A complement deficiency that is a functional deficiency in the complement component C1 inhibitor leading to hereditary angioedema (HAE) involving swelling due to leakage of fluid from blood vessels into connective tissue. (malacards.org)
Gene1
- We inactivated another gal gene, galE , and the mutant was also found to be defective in the catabolism of exogenous galactose but synthesized an apparently normal lipopolysaccharide (LPS). (asm.org)
Regulatory1
- Two renal disorders have been etiologically linked to complement regulatory pathology. (omicsonline.org)
Tissue1
- Complement-mediated tissue injury has also been found to result from bioincompatibility situations such as those encountered in patients undergoing dialysis or cardiopulmonary bypass. (justia.com)
Immunoglobulin2
- HMW agents can induce an immunoglobulin E (IgE) response in susceptible individuals and can cause asthma by an IgE-mediated mechanism, similar to that seen in a patient with atopic asthma. (clevelandclinicmeded.com)
- Immunofluorescence studies show no immunoglobulin or complement deposits. (slideplayer.com)
Inflammatory3
- complement components C5b to C9) and C5a, a potent anaphylatoxin that elicits various inflammatory signals through binding to C5a receptor 1 (C5aR1). (cdc.gov)
- In the study we propose to compare the clinical efficacy of Linezolid in bolus vs Linezolid in continuous infusion in patients with severe sepsis and septic shock (outcome) and to analyse whether significant differences are registered in the coagulation, inflammatory and complement response between the two group of patients.METHODS: A prospective, randomized comparative trial involved not neutropenic patients admitted in ICU from January until March 2004. (unipa.it)
- Dr. Conway disclosed that he holds a patent for the use of the lectinlike domain of thrombomodulin as an anti-inflammatory agent. (medpagetoday.com)
Enzymes3
- The effects of reducing agents on the activities of the wild-type and mutant enzymes indicated the reversibility of disulfide-bond formation, which resulted in three-fold decrease in catalytic efficiency. (proteopedia.org)
- TOF-MS analysis of the inactivated enzyme showed the Scysteinylation of Cys138 in the wild-type and Cys150 in the mutant enzymes. (proteopedia.org)
- This metabolismcalled biotransformationoccurs in the liver where enzymes inactivate a deaden by means of changing it into more water-soluble compounds that can be excreted from the substance. (chesapeakehumane.org)
Potent2
- Fueled by novel research insight and the marketing of the first complement-targeted drugs, a plethora of highly creative treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials. (missouri.edu)
- Activation of complement C5 generates the potent anaphylatoxin C5a and leads to pathogen lysis, inflammation and cell damage. (ox.ac.uk)
Human serum1
- 32. A culture medium according to the claim 31, wherein the autologous human serum is treated to inactivate a complement. (freepatentsonline.com)
Functional1
- These phenotypes were complemented by supplying a functional copy of priA elsewhere in the chromosome. (asm.org)
Bacterial1
- Additionally, the Luminex assay works in a multiplex format, simultaneously detecting four category A and B bacterial bioterrorism agents and is suitable for detecting Brucella in complex samples. (biomedcentral.com)
Mechanism1
- Conclusions: Acid aspiration induces lung injury through a complement- dependent mechanism that leads to microvascular permeability defects. (elsevier.com)
Targeting1
- We also discuss the relative advantages and benefits offered by each complement-targeting approach, including translational considerations that might leverage a more comprehensive clinical intervention for PNH. (nih.gov)
Kidney1
- Associated with other systemic disorders and known etiologic agents (secundary MPGN) or may be primary, without known cause (idiopathic) in the kidney. (slideplayer.com)